 |
Glenn L. Cooper, M.D.
Executive Chairman and Director
Dr. Cooper has served as a member of our board of directors since
October 2009, as our executive chairman since July 2010 and served as
our acting chief executive officer from December 2010 to April 2011. Dr.
Cooper has extensive leadership experience in the pharmaceutical and
biotechnology industries with expertise in transforming development
stage companies into commercial organizations. From 1993 to 2009, Dr.
Cooper was the chairman and chief executive officer of Indevus
Pharmaceuticals, Inc., a specialty pharmaceuticals company. Indevus was
acquired by Endo Pharmaceuticals, Inc. in March 2009. Prior to joining
Indevus, Dr. Cooper held numerous executive level positions, including
president and chief executive officer of Progenitor, Inc., executive
vice president and chief operating officer of Sphinx Pharmaceuticals
Corporation, and various clinical and regulatory positions with Eli
Lilly and Company. Dr. Cooper also serves on the board of directors of
Gentium S.p.A. and Repligen Corporation. Dr. Cooper holds a B.A. from
Harvard College and received his M.D. from Tufts University School of
Medicine. 
|
 |
Bobby W. Sandage, Jr., Ph.D.
President & CEO and Director
Dr. Sandage has served as our president and chief executive officer since April 2011 and has over 30 years of experience in the pharmaceutical industry, most recently as the vice president and head of oncology research and development for Covidien Pharmaceuticals, a specialty pharmaceuticals company, a position he held from March 2010 until March 2011. From November 1991 to December 2009, Dr. Sandage held various positions at Indevus Pharmaceuticals, a specialty pharmaceuticals company, including executive vice president of research and development and chief scientific officer, prior to the sale of the company to Endo Pharmaceuticals. Prior to joining Indevus Pharmaceuticals, from 1981 to 1991, Dr. Sandage held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont Critical Care (formerly American Critical Care) and Merrell Dow Pharmaceuticals. Dr. Sandage is currently a member of the board of directors of Gentium S.p.A., a pharmaceutical company. Dr. Sandage has also served as a member of the board of directors of Osteologix, Inc. and Genta Incorporated. Dr. Sandage has a B.S. in pharmacy from the University of Arkansas and a Ph.D. in clinical pharmacy from Purdue University.
|
 |
Noah D. Beerman
Executive Vice President & COO
Noah D. Beerman has served as our executive vice president and chief operating officer since September 2011 and has over 25 years of experience in the biopharmaceutical industry. Mr. Beerman, who has been a consultant to our company since May 2011, served as president and chief executive officer and a director of Galena Biopharma, formerly RXi Pharmaceuticals Corporation, from November 2009 until April 2011. Prior thereto, he spent more than 10 years at Indevus Pharmaceuticals, Inc. serving most recently as executive vice president, chief business officer from September 2004 until the sale of the company to Endo Pharmaceuticals, Inc. in 2009. Prior to joining Indevus, from 1995 to 1997, Mr. Beerman was vice president responsible for health care at Technology Management and Funding. Mr. Beerman previously served in a variety of business development and scientific capacities at Creative BioMolecules, Sandoz AG, and Repligen. Mr. Beerman received an M.B.A. from Northeastern University’s High Technology Program and a B.S. in molecular genetics from the University of Rochester.
|
|
Dale Ritter
Senior Vice President, Finance & CFO
Mr. Ritter has served as our senior vice president, finance, chief accounting officer and acting chief financial officer since May 2011. Mr. Ritter has over 20 years of experience in the pharmaceutical industry. From September 2009 until joining us, he was an independent consultant, most recently serving as a financial consultant to Helicos BioSciences Corporation, an innovative genetic analysis technologies company, from January to May 2011. From 1994 to 2009, Mr. Ritter was the senior vice president of finance and chief accounting officer at Indevus Pharmaceuticals until the sale of the company to Endo Pharmaceuticals. Mr. Ritter has a B.A. from Syracuse University and an MBA from Babson College Graduate School of Business Administration.
|
|
Karin Hehenberger, M.D., Ph.D.
Senior Vice President of Scientific Affairs
Dr. Hehenberger has served as our Senior Vice President of Scientific Affairs since December 2011 and has over 15 years of experience in the healthcare industry. Most recently, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial, and commercial partners in the diabetes community. Prior to JDRF, Dr. Hehenberger worked at Johnson & Johnson as Vice President of Metabolic Strategy and Business Development. Dr. Hehenberger also has experience in public and private equity, having been a partner in Scandinavian Life Science Venture, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, on the senior management team of Eyetech Pharmaceuticals, and earlier in her career as a strategic management consultant at McKinsey & Co. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School.
|
